Translate this page into:
Editorial Commentary
doi:
10.4103/2278-330X.187563
Lung cancer in India: Current status and promising strategies
1
Asian Cancer Institute, KJ Somaiya Ayurvihar, Mumbai, Maharashtra
2
Avinash Cancer Clinic, Pune, Maharashtra
3
Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka
4
Yashoda Hospital, Hyderabad, Telangana
5
HCG Cancer Center, New Delhi
6
Kovai Hospital, Coimbatore, Tamil Nadu
7
Fortis Hospital, Kolkata, West Bengal
8
Indian Cancer Society, Mumbai, Maharashtra
9
Indraprastha Apollo Hospital, New Delhi
10
Max Hospital, New Delhi
11
Max Hospital, New Delhi
12
Deenanath Mangeshkar Hospital, Pune, Maharashtra
*Corresponding author: Dr. P. M. Parikh. purvish1@gmail.com
MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.
References
- Parikh PM, editor. Lung Cancer Monograph 2012. ICP, API; 2012.
- Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: Results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005;366:1527-37.
- Parikh PM, Vaid A, Advani SH, Digumarti R, Madhavan J, Nag S, et al. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. J Clin Oncol 2011;29:4129-36.
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008;26:3543-51.
- Hirsch FR, Varella-Garcia M, Bunn PA Jr., Franklin WA, Dziadziuszko R, Thatcher N, et al. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 2006;24:5034-42.
- Parikh P, Puri T. Personalized medicine: Lung cancer leads the way. Indian J Cancer 2013;50:77-9.
- Chang A, Parikh P, Thongprasert S, Tan EH, Perng RP, Ganzon D, et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: Subset analysis from the ISEL study. J Thorac Oncol 2006;1:847-55.
- Parikh PM. Treatment of lung cancer in the elderly. Inj J Med Peadiatr Oncol 1999;2:140-7.
- Vanita N, Pinnati R, Joshi A, Patil VM, Prabhash K. Lung cancer in the Indian subcontinent. SAJC 2016;5:95-103.
- Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. [Last accessed on 2016 Feb 20].
- Available from: http://www.indiancancersociety.org/cancer-registry/cancer-registry.aspx. [Last accessed on 2016 Feb 20].
- Chougule A, Prabhash K, Noronha V, Joshi A, Thavamani A, Chandrani P, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 2013;8:e76164.
- Noronha V, Joshi A, Gokarn A, Sharma V, Patil V, Janu A, et al. The importance of brain metastasis in EGFR mutation positive NSCLC patients. Chemother Res Pract 2014;2014:856156.
- Veldore VH, Patil S, Prabhudesai S, Satheesh CT, Shashidhara HP, Krishnamoorthy N, et al. Targeted therapy management in NSCLC patients using cytology: Experience from a tertiary care cancer center. Mol Diagn Ther 2016;20:119-23.
- Available from: http://www.cancerprogress.net/cca/advance-year-cancer-immunotherapy. [Last accessed on 2016 Feb 20].
- Juntu J, Sijbers J, De Backer S, Rajan J, Van Dyck D. Machine learning study of several classifiers trained with texture analysis features to differentiate benign from malignant soft-tissue tumors in T1-MRI images. J Magn Reson Imaging 2010;31:680-9.
- Walia S, Sharma S, Markand Kulurkar P, Patial V, Acharya A. A bimodal molecular imaging probe based on chitosan encapsulated magneto-fluorescent nanocomposite offers biocompatibility, visualization of specific cancer cells in vitro and lung tissues in vivo. Int J Pharm 2016;498:110-8.
- Sampedro F, Escalera S, Domenech A, Carrio I. A computational framework for cancer response assessment based on oncological PET-CT scans. Comput Biol Med 2014;55:92-9.